The sulfamide moiety has been utilized to design novel HDAC inhibitors. The potency and selectivity of
these inhibitors were influenced both by the nature of the scaffold, and the capping group. Linear longchain-
based analogs were primarily HDAC6-selective, while analogs based on the lysine scaffold resulted
in potent HDAC1 and HDAC6 inhibitors.